Clinical trial
Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment
NCT02581995 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment
- Lead sponsor
- Bayer
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 19, 2015
- Completion date
- August 9, 2017
- Enrollment
- 560 (actual)
- Sites
- 76
Conditions
As the registry lists them; a condition with its own page is linked.